Privia Health Group (NASDAQ:PRVA) Trading 9.4% Higher on Better-Than-Expected Earnings

Privia Health Group, Inc. (NASDAQ:PRVA) shot up 9.4% during mid-day trading on Thursday following a stronger than expected earnings report. The stock traded as high as $24.44 and last traded at $24.7720. 147,233 shares changed hands during mid-day trading, a decline of 79% from the average session volume of 703,620 shares. The stock had previously closed at $22.65.

The company reported $0.25 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.21. The business had revenue of $541.17 million during the quarter, compared to the consensus estimate of $516.61 million. Privia Health Group had a return on equity of 2.52% and a net margin of 0.89%.The business’s revenue for the quarter was up 17.4% on a year-over-year basis. During the same period in the previous year, the company posted $0.21 earnings per share.

Key Privia Health Group News

Here are the key news stories impacting Privia Health Group this week:

• Positive Sentiment: Reported Q4 and full‑year 2025 results topped guidance and street estimates—revenue and EPS beats, adjusted EBITDA and other operating metrics came in at or above the high end of guidance. This is the primary driver of the intraday rally. Privia Health Reports Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Company issued 2026 guidance above consensus: GAAP revenue guide ~$2.35–$2.45B and ~20% adjusted EBITDA growth at the midpoint, signaling continued top‑line and profitability expansion — a clear positive for valuation and analyst sentiment. Privia Health: Q4 Earnings Snapshot
• Positive Sentiment: Strong balance sheet and cash generation: year‑end cash ≈$480M, no debt, and historic free cash flow conversion — supports growth initiatives and reduces financing risk. Privia Health Group, Inc. Reports Strong 2025 Financial Results
• Neutral Sentiment: Management will host an earnings call/webcast to discuss results and outlook; investors should listen for details on execution, MA risk arrangements and M&A plans that could move the stock further. Privia Health (NASDAQ:PRVA) Reports Strong Q4 CY2025
• Negative Sentiment: Large non‑cash stock‑based compensation (~$71M in 2025) and other non‑GAAP adjustments inflate adjusted metrics; investors should discount some of the headline adjusted figures and watch dilution/comp expense trends. Privia Health beats estimates on earnings and revenue
• Negative Sentiment: Corporate disclosures note management has not reconciled forward‑looking non‑GAAP measures to GAAP (and there were recent insider share sales flagged in filings), both of which are potential governance/visibility concerns for some investors. Privia Health (PRVA) Reports Q4 Earnings: What Key Metrics Have to Say

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Barclays boosted their target price on shares of Privia Health Group from $22.00 to $23.00 and gave the stock an “equal weight” rating in a research note on Monday, November 10th. Truist Financial reaffirmed a “buy” rating and set a $31.00 price objective (up from $30.00) on shares of Privia Health Group in a research report on Monday, November 10th. Stephens reissued an “overweight” rating and set a $32.00 target price on shares of Privia Health Group in a research report on Thursday, December 4th. Wolfe Research set a $31.00 price target on Privia Health Group in a report on Tuesday, January 6th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $36.00 price target on shares of Privia Health Group in a research note on Thursday. Thirteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Privia Health Group has a consensus rating of “Moderate Buy” and an average price target of $30.71.

Insider Buying and Selling at Privia Health Group

In related news, CFO David Mountcastle sold 23,887 shares of the stock in a transaction on Friday, December 12th. The shares were sold at an average price of $25.03, for a total transaction of $597,891.61. Following the completion of the sale, the chief financial officer owned 172,909 shares in the company, valued at $4,327,912.27. This represents a 12.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Matthew Shawn Morris sold 13,647 shares of Privia Health Group stock in a transaction on Friday, December 12th. The shares were sold at an average price of $25.01, for a total transaction of $341,311.47. Following the completion of the transaction, the director owned 68,188 shares in the company, valued at approximately $1,705,381.88. This represents a 16.68% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 10.70% of the stock is owned by corporate insiders.

Institutional Trading of Privia Health Group

A number of hedge funds have recently added to or reduced their stakes in the stock. Great Lakes Advisors LLC purchased a new position in shares of Privia Health Group during the 3rd quarter worth approximately $4,487,000. Advantage Alpha Capital Partners LP purchased a new stake in shares of Privia Health Group in the second quarter valued at approximately $3,941,000. Hsbc Holdings PLC grew its holdings in Privia Health Group by 69.2% during the second quarter. Hsbc Holdings PLC now owns 113,718 shares of the company’s stock worth $2,549,000 after acquiring an additional 46,526 shares during the period. Edgestream Partners L.P. purchased a new position in Privia Health Group in the second quarter worth $2,209,000. Finally, Bailard Inc. acquired a new stake in Privia Health Group in the second quarter valued at $531,000. 94.48% of the stock is owned by institutional investors and hedge funds.

Privia Health Group Stock Performance

The company has a market capitalization of $3.06 billion, a PE ratio of 191.63, a price-to-earnings-growth ratio of 1.59 and a beta of 0.83. The firm’s 50-day simple moving average is $23.06 and its 200 day simple moving average is $23.44.

About Privia Health Group

Privia Health Group (NASDAQ: PRVA) is a physician enablement company that partners with independent physicians, medical groups and health systems to transform the delivery of patient care. Through a clinically integrated network and a proprietary technology platform, the company supports providers in managing population health, delivering coordinated care and optimizing financial performance under both fee-for-service and value-based reimbursement models.

Founded in 2016 and headquartered in McLean, Virginia, Privia Health has rapidly expanded its footprint to serve multiple metropolitan markets across the United States.